A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment
2017 ◽
Vol 71
(6)
◽
pp. e12955
◽
Keyword(s):
2017 ◽
Vol 389
(10077)
◽
pp. 1399-1409
◽
Keyword(s):
Keyword(s):
Keyword(s):
2018 ◽
Vol 138
◽
pp. 253-261
◽
2016 ◽
Vol 18
(7)
◽
pp. 711-715
◽
Keyword(s):